T-E Pharma

T-E Pharma Holding owns two subsidiaries: Immunwork, Inc. and T-E Meds, Inc. Immunwork, founded in 2014, is dedicated to the research, development and commercialization of innovative therapeutics based on our proprietary “T-E pharmaceuticals” platform. The drug-design platform is employed in the construction of ultra-long-acting peptide therapeutics, antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and other advanced pharmaceutical modalities. To focus development efforts in the ADC/ARC field, Immunwork established T-E Meds, Inc. in 2022 to take over and further develop its ADC and ARC platforms and associated drug candidates. Among our leading clinical assets, TE-8214 and TE-8105, both developed using its ultra-long-acting platform, represent key milestones. TE-8214, targeting neuroendocrine tumors and acromegaly, successfully completed its Phase I trial in June 2025. TE-8105, aimed at treating obesity (including weight management), type 2 diabetes, and fatty liver disease, completed its Phase I/IIA trial in November 2025. Both candidates have demonstrated good tolerability with no significant side effects. Phase II trials are currently in active preparation. T-E Meds, founded in 2022, focuses exclusively on antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Unlike conventional ADC/ARC platforms that often suffer from low product homogeneity and complex manufacturing processes, T-E Meds employs a proprietary bioconjugation platform that enables streamlined, enzyme-free, site-specific conjugation. This approach yields homogeneous ADCs/ARCs with high drug-to-antibody ratio (DAR), excellent yield, high purity, and flexible payload incorporation. T-E Meds is advancing a robust pipeline of preclinical candidates targeting various cancers, with IND filings for lead candidate planned in 2026 H1.